Single Adverse Event Nets Clinical Hold for Avidity’s DM1 Study

The FDA has placed a partial clinical hold on Avidity Biosciences’ phase 1/2 MARINA study after one person treated with AOC 1001, an investigational gene therapy for myotonic dystrophy type 1 (DM1), experienced a serious adverse event.
Source: Drug Industry Daily